Stock Detail
VICAL INCORPORATED
Biotechnology
VICL @ Yahoo Finance | VICL Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $3.53 | $3.67 | $0.03 | 0.86% | 0.00 | $3.50 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $3.46 | $3.45 | 730,456 | 253.74M | 735,135.5 | -35.30 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 3.77 | 3.65 | 3.55 | 3.43 | 3.33 |
Stock Profile
Vical Incorporated engages in the research and development of biopharmaceutical products for the prevention and treatment of serious or life-threatening diseases. The company focuses on the development of biopharmaceutical product candidates based on its patented deoxyribonucleic acid (DNA) delivery technologies. It develops various DNA-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cancer, and cardiovascular diseases. Vical primarily develops its cancer immunotherapeutics, Allovectin-7 and IL-2/Electroporation, as well as a plasmid DNA vaccine for cytomegalovirus. Allovectin-7, which completed its Phase II clinical trials, is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and ß2 microglobulin, which together form a Class I Major Histocompatibility Complex antigen. Allovectin-7 is being developed as a treatment for metastatic melanoma, a form of skin cancer. IL-2/Electroporation program that is in Phase 1 clinical testing is a gene-based, electroporation enhanced delivery of interleukin-2, or IL-2, a potent immunotherapeutic agent, as a treatment for solid tumors, with an initial indication in metastatic melanoma. Vical also develops an anthrax vaccine, which is in Phase 1 clinical testing. The company was incorporated in 1987 and is based in San Diego, California.